Narrative review highlights disrupted mucosal immunity and microbiome imbalances in inflammatory bowel disease, indicating pathways for targeted anti-inflammatory therapies.
Research on IBDs has identified disrupted immune responses in the gastrointestinal mucosa and putative disruptions in the gut microbiome as causative agents. This work has led to better therapeutic control of IBDs with the use of various antiinflammatory agents.
No takes yet. Share an insight, caveat, or question.
John T. Chang (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: